RxDoctor Payments Data

David Utlak, MD

Cardiovascular Disease · Canton, OHNPI 1548269756

Payments from drug & device makers

$12,811in general payments, 2019–2025

Across 322 payments — averaging $39.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$9K
  • Johnson & Johnson$809
  • Merck$510
  • Boehringer Ingelheim$331
  • Amarin Pharma, Inc.$299
  • E.r. Squibb & Sons, L.L.C.$272
  • plus $1K from 16 others

What the payments were for

  • Speaking & faculty fees$8,11563%
  • Travel & lodging$100%
  • Food & beverage$4,60236%
  • Education$841%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,811 in reported general payments places this provider in the 75th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$113,087
Medicare patients
216
Services billed
1,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban135$131,784
EliquisApixaban108$98,167
EntrestoSacubitril/Valsartan84$84,266
BrilintaTicagrelor21$20,163
MultaqDronedarone Hcl13$9,683
Metoprolol Succinate436$5,016
Ranolazine ErRanolazine57$4,208
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide62$2,326
Valsartan66$2,227
Potassium Chloride127$2,189
Diltiazem 24hr Er (Cd)Diltiazem Hcl55$1,686
SotalolSotalol Hcl32$781
Ezetimibe27$773
Atorvastatin Calcium80$679
ClopidogrelClopidogrel Bisulfate80$657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$809$131,784135 claims
NovartisEntresto$9,347$84,26684 claims
AstraZenecaBrilinta$123$20,16321 claims
Sanofi-aventis U.S. LLCMultaq$138$9,68313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →